November 2008 Pompe Program Update 2

Genzyme Pompe Program Update- November 17, 2008 We would like to take this opportunity to provide an important update to the Pompe Community. The US Food and Drug Administration (FDA) has informed Genzyme that the FDA plans an accelerated approval for alglucosidase...

November 2008 Pompe Program Update

Genzyme Program Update November 10th, 2008 Genzyme would like to take this opportunity to provide an update to the Pompe Community. The US Food and Drug Administration (FDA) held a meeting of its Endocrinologic and Metabolic Drugs Advisory Committee on October 21,...

IPA FAQs About the Myozyme Supply Problem

A compilation of the most pertinent information regarding the MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More supply issue. The IPA has done its best to gather the most relevant and commonly asked...

AMDA Letter to Patients Regarding Supply Situation

By: Tiffany House–AMDA President posted on: January 17, 2009 The AMDA is writing to our Pompe patient community to let everyone know that the AMDA has been working closely with the IPA and Genzyme in order to get communication out to our patient population about...

AMDA Statement Regarding the Management of “Myozyme” supply

The AMDA is writing to our Pompe patient community to let everyone know that the AMDA has been working closely with the IPA and Genzyme in order to get communication out to our patient population about the status of the MyozymeA form of enzyme replacement therapy used...

IPA Statement Regarding the Management of Myozyme Supply

Since the first market approval of MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More, the IPA has liaised directly with Genzyme LSDA group of diseases in which substances build up inside lysosomes...